A summary of the main changes, and some smaller but tricky changes

Prepared by Mark Short, Cancer Data and Monitoring Unit, Australian Institute of Health and Welfare, with assistance from the Australasian Association of Cancer Registries.

Neuroendocrine tumours
Nearly all neuroendocrine tumours are now behaviour 3.
- In the 3-digit group 815 the only remaining non-malignant terms are under 8150/0.
- In the 3-digit group 824 the only remaining non-malignant terms are under 8245/1 and 8248/1.
- In the 3-digit group 868–870 the only remaining non-malignant term is under 8683/0.

Use of the word “carcinoma” with behaviour 1
Two terms that contain the word “carcinoma” have behaviour 1.
- 8323/1 Clear cell papillary renal cell carcinoma (C64.9) – This is a new term.
- 8335/1 Follicular carcinoma, encapsulated, NOS (C73.9) – This was /3 in 3.1.

Cystic, mucinous and serous neoplasms
This section (844–849) has undergone extensive rearrangement. Eighteen terms have changed their first 4 digits. No terms have changed behaviour but note the following.
- Serous borderline tumour, micropapillary variant is a new term that is coded as 8460/2. This would have been recorded as serous borderline tumour 8442/1 in ICD-O-3.1.
- Serous tubal intraepithelial carcinoma (STIC) is a new term that is coded as 8441/2.

Pleomorphic lobular carcinoma (in situ)
The invasive and non-invasive versions of this neoplasm have different 4-digit codes.
- 8519/2 Lobular carcinoma in situ, pleomorphic (C50._).
- 8520/3 Lobular carcinoma, pleomorphic (C50._).

Thymomas
Nearly all thymomas (858) are now behaviour 3. The only remaining non-malignant terms are under 8580/0, 8580/1 and 8587/0.
Dermatofibrosarcoma protuberans

The two codes for this neoplasm, 8832/3 and 8833/3, have changed behaviour from 3 to 1. This will render such neoplasms out of scope for most registries. However, two new malignant terms, i.e. in scope, have been introduced under 8832/3.

<table>
<thead>
<tr>
<th>Old code</th>
<th>Term</th>
<th>New code</th>
</tr>
</thead>
<tbody>
<tr>
<td>8832/3</td>
<td>Dermatofibrosarcoma protuberans, NOS (C44.<em>) Dermatofibrosarcoma, NOS (C44.</em>)</td>
<td>Moved to /1</td>
</tr>
<tr>
<td>8833/3</td>
<td>Pigmented dermatofibrosarcoma protuberans (C44.<em>) Bednar tumor (C44.</em>)</td>
<td>Moved to /1</td>
</tr>
<tr>
<td>None *</td>
<td>Dermatofibrosarcoma protuberans, fibrosarcomatous (C44.<em>) Dermatofibrosarcoma, sarcomatous (C44.</em>)</td>
<td>8832/3</td>
</tr>
</tbody>
</table>

* These terms were not listed in ICD-O-3.1 but would have been coded as 8832/3 because the "NOS" versions were listed under 8832/3.

Gastrointestinal stromal tumours

All GIST terms are now malignant (8936/3).

Haemangiopericytoma merged with solitary fibrous tumour

9150 (haemangiopericytoma) has been deleted and all terms moved to 8815 (solitary fibrous tumour).

Ewing sarcoma

Ewing sarcoma (9260/3) has moved to, and is now the preferred term for, 9364/3 (peripheral neuroectodermal tumour). Note, though, that the 4-digit code 9260 has not been deleted because a new term has been introduced under 9260/0.

Introduction of several new /1 codes in the haematological section

- New terms have been introduced under the new codes 9591/1, 9673/1, 9680/1, 9695/1, 9702/1, 9761/1 and 9823/1.
- 9725/3 and 9971/3 have changed behaviour from 3 to 1.
- Some, but not all, terms from existing /3 codes have been moved to new /1 codes: one term has moved from 9709/3 to /1, two terms have moved from 9718/3 to /1, and three terms have moved from 9751/3 to /1.

Consolidation of some paired leukaemia/lymphoma codes

- CLL/SLL: 9670/3 deleted. Terms moved to 9823/3.
- B lymphoblastic leukaemia/lymphoma, NOS: 9728/3 and 9836/3 deleted. Terms moved to 9811/3.
- T lymphoblastic leukaemia/lymphoma: 9729/3 deleted. Term moved to 9837/3.
- Burkitt (cell) lymphoma/leukaemia: 9826/3 deleted. Terms moved to 9687/3.
Grades for lymphomatoid granulomatosis

Grades have been introduced for this term (9766). Grades 1 and 2 have behaviour 1 while grade 3 has been assigned to the new 5-digit code 9766/3.

See also

See also the section “Site-specific changes of behaviour” in the document “Terms that are changing behaviour”.